Cannabis Made $30 Billion Last Year. Operators Still Can’t Tell You What a Single Batch Actually Costs.

The U.S. cannabis industry moved more than $30 billion in regulated sales in 2025. That is a number that sounds like maturity — like an industry that has arrived. And yet, a significant portion of the licensed operators who contributed to that total cannot answer a question that any first-year business school student would consider foundational: What does it actually cost to produce one batch of product?

That gap — between impressive top-line revenue and murky, incomplete cost visibility — is at the center of what many financial operators are now calling the industry’s next real crisis. Not a regulatory one, for once. A management one.

The timing could hardly be worse, or more clarifying.

A Volatile Floor, a Uncertain Ceiling

Cannabis Benchmarks, which tracks wholesale pricing across legal markets, reported this spring that bulk flower prices have been fluctuating in a narrow but unstable band — roughly $987 to $1,007 per pound in recent weeks. That may look like stability on a chart, but for operators pricing products weeks or months in advance, a 2% swing at the wholesale level can erase what little margin they’ve built into their SKUs.

The volatility isn’t new. What is new is the moment in which it’s hitting.

Rescheduling from Schedule I to Schedule III — finalized by the Department of Justice last week — has fundamentally changed the legal and financial landscape. The DEA has already begun rolling out a registration portal for state-licensed medical dispensaries, and the Treasury Department followed within days with a joint IRS announcement: tax guidance aimed at relieving the crushing burden of Section 280E is forthcoming for businesses in the medical marijuana space.

For years, 280E — the IRS provision that denied cannabis businesses standard business deductions — functioned as an unofficial profit tax on top of a profit tax. Operators absorbed it, mostly, by guessing at margins and hoping the quarter came out clean.

Now those deductions are potentially coming back. And the uncomfortable truth is that many operators don’t have clean enough cost accounting to even know how much they’ll benefit — or how to redirect those savings strategically.

The Batch Problem

Cannabis is, at its core, a batch manufacturing business. Every flower run, every infused pre-roll, every edible SKU originates from a discrete production event with its own inputs, its own labor hours, its own testing fees. In pharmaceutical and food manufacturing — industries that cannabis has always resembled more than it has resembled agriculture — profitability lives and dies at the batch level.

Cannabis operators, as a class, have never fully adopted that discipline.

A recent analysis from Cannabis Industry Journal laid out the problem in unusually direct terms. The industry’s cost structure breaks into five core buckets: direct labor, direct materials (inputs, packaging, testing, waste), facility costs (rent, utilities, security, equipment), office and general overhead, and inventory adjustments including depreciation. Most operators track the first two adequately. The rest — the indirect costs that can represent a substantial fraction of total production expense — frequently get lumped, averaged, or ignored.

“Pricing volatility alone does not eliminate profitability,” the analysis notes. “But pricing volatility combined with incomplete cost allocation magnifies risk.”

That’s a diplomatic way of saying: operators are flying blind, and the wind just picked up.

The GMP Pressure Is Real

There’s a second current pushing from a different direction: quality standards.

At ICBC Berlin this month — the largest cannabis business conference outside North America — the conversation among international producers was dominated by cGMP compliance. Current Good Manufacturing Practices, the pharmaceutical-grade production standards that govern drug manufacturing in regulated markets, are increasingly being demanded by European buyers, by multi-state operators seeking to enter new markets, and by retailers who’ve been burned by contamination recalls.

Implementing GMP isn’t just a quality story. It’s an accounting story. GMP compliance requires tracking inputs, contamination controls, and post-harvest handling at a granularity that forces operators to confront exactly the cost-structure questions they’ve been avoiding. You cannot demonstrate pharmaceutical-grade consistency without knowing, precisely, what went into each batch and what it cost to produce.

For the domestic market, GMP is not yet legally required at the federal level. But operators who want to compete internationally — or who are positioning for a post-rescheduling market that may eventually see cannabis products regulated more like pharmaceuticals — are finding that GMP implementation and batch-level cost accounting arrive as a package deal.

The 280E Relief Wildcard

Here’s the perverse opportunity embedded in this moment: if Treasury and the IRS follow through on the promised 280E guidance for medical cannabis businesses, operators will suddenly be able to deduct ordinary and necessary business expenses for the first time. Rent. Salaries. Professional fees. Equipment depreciation.

For businesses that have been operating under 280E, those deductions can shift effective tax rates dramatically — in some cases from the 70% range down to something that resembles a normal business.

But capturing that benefit, and deploying it intelligently, requires knowing your actual cost structure. Operators who have been sloppy about indirect cost allocation won’t be able to tell their accountants what to deduct, or evaluate whether a given facility or product line is genuinely profitable once the tax distortion is removed.

The rescheduling era isn’t just a regulatory pivot. It’s a stress test on every financial assumption the industry has been running on for a decade.

What Survival Looks Like

Cannabis Business Journal’s analysis suggests that operators who build batch-level cost tracking into their operations — rather than relying on averages and gut checks — will have a structural advantage as markets tighten and the regulatory environment normalizes. The math isn’t complicated. A 10-20% miscalculation in cost-per-gram doesn’t just affect this quarter’s margin. It corrupts pricing strategy, SKU rationalization decisions, and expansion modeling.

The industry has survived this long on revenue growth papering over operational sloppiness. That era appears to be ending. Wholesale prices are compressing. Tax relief is coming — but only for operators organized enough to use it. And GMP-minded buyers, domestic and international, are starting to ask questions that require real answers.

Thirty billion dollars in revenue is a milestone. It’s also a accountability moment. The operators who will still be standing five years from now are the ones who, right now, can answer the basic question: what does this product actually cost to make?

The ones who can’t have been warned.

Caleb Quinn covers cannabis business and finance for CannabisInquirer.com. Tips and financials: caleb@cannabisinquirer.com